These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 38349726)

  • 41. The first MASH drug therapy on the horizon: Current perspectives of resmetirom.
    Petta S; Targher G; Romeo S; Pajvani UB; Zheng MH; Aghemo A; Valenti LVC
    Liver Int; 2024 Jul; 44(7):1526-1536. PubMed ID: 38578141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic Muddle. MASLD and MASH on the Horizon.
    Meagher T
    J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting nuclear receptors for NASH/MASH: From bench to bedside.
    Sinha RA
    Liver Res; 2024 Mar; 8(1):34-45. PubMed ID: 38544909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis.
    Qin X; Liu J
    Acta Biomater; 2024 Aug; 184():37-53. PubMed ID: 38879104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD.
    Johanns M; Haas JT; Raverdy V; Vandel J; Chevalier-Dubois J; Guille L; Derudas B; Legendre B; Caiazzo R; Verkindt H; Gnemmi V; Leteurtre E; Derhourhi M; Bonnefond A; Froguel P; Eeckhoute J; Lassailly G; Mathurin P; Pattou F; Staels B; Lefebvre P
    JHEP Rep; 2024 Jan; 6(1):100948. PubMed ID: 38125300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review.
    Sanyal AJ; Husain M; Diab C; Mangla KK; Shoeb A; Lingvay I; Tapper EB
    Am Heart J Plus; 2024 May; 41():100386. PubMed ID: 38623572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apoptosis antagonizing transcription factor-mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis-hepatocellular carcinoma.
    Srinivas AN; Suresh D; Chidambaram SB; Santhekadur PK; Kumar DP
    J Cell Physiol; 2024 Jan; 239(1):135-151. PubMed ID: 37942831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population.
    Iruzubieta P; Mayo R; Mincholé I; Martínez-Arranz I; Arias-Loste MT; Ibañez-Samaniego L; Ampuero J; Abad J; Martín-Mateos R; Fernández-Laso AB; Albillos A; Bañares R; Calleja JL; Romero-Gómez M; Aller R; Crespo J
    United European Gastroenterol J; 2024 Aug; ():. PubMed ID: 39099245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses.
    Navarro-Masip È; Mestres Petit N; Salinas-Roca B; Herrerías F; Vilardell F; de la Fuente MC; Pallares J; Santamaría M; Zorzano-Martínez M; Sánchez E; Matías-Guiu X; López-Cano C; Soler AG; León-Mengíbar J; Bueno M; Lecube A
    Obes Facts; 2024 Jun; ():1-10. PubMed ID: 38934179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease.
    Sarabhai T; Kahl S; Gancheva S; Mastrototaro L; Dewidar B; Pesta D; Ratter-Rieck JM; Bobrov P; Jeruschke K; Esposito I; Schlensak M; Roden M
    Metabolism; 2024 Feb; 151():155762. PubMed ID: 38122893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
    Kokkorakis M; Muzurović E; Volčanšek Š; Chakhtoura M; Hill MA; Mikhailidis DP; Mantzoros CS
    Pharmacol Rev; 2024 May; 76(3):454-499. PubMed ID: 38697855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut microbes, diet, and genetics as drivers of metabolic liver disease: a narrative review outlining implications for precision medicine.
    Hermanson JB; Tolba SA; Chrisler EA; Leone VA
    J Nutr Biochem; 2024 Nov; 133():109704. PubMed ID: 39029595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
    J Hepatol; 2024 Aug; 81(2):195-206. PubMed ID: 38548067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.
    Kocas-Kilicarslan ZN; Cetin Z; Faccioli LAP; Motomura T; Amirneni S; Diaz-Aragon R; Florentino RM; Sun Y; Pla-Palacin I; Xia M; Miedel MT; Kurihara T; Hu Z; Ostrowska A; Wang Z; Constantine R; Li A; Taylor DL; Behari J; Soto-Gutierrez A; Tafaleng EN
    Gastro Hep Adv; 2024; 3(1):67-77. PubMed ID: 38292457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role and therapeutic perspectives of extracellular vesicles derived from liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease.
    Li W; Yu L
    Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):355-369. PubMed ID: 38833340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.